These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 31473027)

  • 21. Trends in Antihypertensive Medication Use Among US Patients With Resistant Hypertension, 2008 to 2014.
    Hwang AY; Dave C; Smith SM
    Hypertension; 2016 Dec; 68(6):1349-1354. PubMed ID: 27777360
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Salt, the renin-angiotensin-aldosterone system and resistant hypertension.
    Shimosawa T
    Hypertens Res; 2013 Aug; 36(8):657-60. PubMed ID: 23912973
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of spironolactone on blood pressure in subjects with resistant hypertension.
    Chapman N; Dobson J; Wilson S; Dahlöf B; Sever PS; Wedel H; Poulter NR;
    Hypertension; 2007 Apr; 49(4):839-45. PubMed ID: 17309946
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Correlations between blood pressure, blood volume and plasma renin during therapy with diuretics in essential hypertension. Comparison between the mineralocorticoid antagonist spironolactone and the "loop" diuretic mefruside].
    Beretta-Piccoli C; Weidmann P; de Châtel R; Hirsch D; Reubi FC
    Schweiz Med Wochenschr; 1977 Jan; 107(4):104-15. PubMed ID: 834983
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hypertension in chronic kidney disease-treatment standard 2023.
    Georgianos PI; Agarwal R
    Nephrol Dial Transplant; 2023 Nov; 38(12):2694-2703. PubMed ID: 37355779
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Addition of spironolactone in patients with resistant arterial hypertension (ASPIRANT)--study protocol.
    Vaclavik J; Sedlak R; Plachy M; Navratil K; Plasek J; Husar R; Kocianova E; Taborsky M
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2011 Jun; 155(2):143-8. PubMed ID: 21804623
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Spironolactone versus sympathetic renal denervation to treat true resistant hypertension: results from the DENERVHTA study - a randomized controlled trial.
    Oliveras A; Armario P; Clarà A; Sans-Atxer L; Vázquez S; Pascual J; De la Sierra A
    J Hypertens; 2016 Sep; 34(9):1863-71. PubMed ID: 27327441
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Systematic Review Article: New Drug Strategies for Treating Resistant Hypertension-the Importance of a Mechanistic, Personalized Approach.
    Nardoianni G; Pala B; Scoccia A; Volpe M; Barbato E; Tocci G
    High Blood Press Cardiovasc Prev; 2024 Mar; 31(2):99-112. PubMed ID: 38616212
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacological interventions for hypertension in children.
    Chaturvedi S; Lipszyc DH; Licht C; Craig JC; Parekh R
    Evid Based Child Health; 2014 Sep; 9(3):498-580. PubMed ID: 25236305
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Resistant hypertension: an overview.
    Pedrinelli R; Dell'omo G; Cameli M; Cerbai E; Coiro S; Emdin M; Liga R; Marcucci R; Morrone D; Palazzuoli A; Savino K; Padeletti L; Ambrosio G;
    Minerva Cardioangiol; 2018 Jun; 66(3):337-348. PubMed ID: 28880055
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of spironolactone on blood pressure and the renin-angiotensin-aldosterone system in oligo-anuric hemodialysis patients.
    Gross E; Rothstein M; Dombek S; Juknis HI
    Am J Kidney Dis; 2005 Jul; 46(1):94-101. PubMed ID: 15983962
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [On the way to achieve hypertension treatment goals: results of the open observational program AESCULAP (exforge--clinical safety and efficiency of using a double combination of antihypertensive drugs in patients with uncontrolled blood pressure)].
    Chazova IE; Martynyuk TV
    Ter Arkh; 2013; 85(9):35-45. PubMed ID: 24261228
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Renal safety outcomes of spironolactone in patients with resistant hypertension.
    Galceran I; Vázquez S; Durán X; Outón S; Pascual J; Oliveras A
    Nefrologia (Engl Ed); 2020; 40(4):414-420. PubMed ID: 31898989
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Low dose spironolactone reduces blood pressure in patients with resistant hypertension and type 2 diabetes mellitus: a double blind randomized clinical trial.
    Oxlund CS; Henriksen JE; Tarnow L; Schousboe K; Gram J; Jacobsen IA
    J Hypertens; 2013 Oct; 31(10):2094-102. PubMed ID: 24107738
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Spironolactone and doxazosin treatment in patients with resistant hypertension.
    Rodilla E; Costa JA; Pérez-Lahiguera F; Baldó E; González C; Pascual JM
    Rev Esp Cardiol; 2009 Feb; 62(2):158-66. PubMed ID: 19232189
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Resistant hypertension.
    Viera AJ
    J Am Board Fam Med; 2012; 25(4):487-95. PubMed ID: 22773717
    [TBL] [Abstract][Full Text] [Related]  

  • 37. An Update on Refractory Hypertension.
    Matanes F; Khan MB; Siddiqui M; Dudenbostel T; Calhoun D; Oparil S
    Curr Hypertens Rep; 2022 Jul; 24(7):225-234. PubMed ID: 35384577
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of effects of low dose of spironolactone and a thiazide diuretic in patients with hypertension treated with an angiotensin-converting enzyme inhibitor or an angiotensin type 1 receptor blocker.
    Yutaka M; Mifune M; Kubota E; Itoh H; Saito I
    Clin Exp Hypertens; 2009 Nov; 31(8):648-56. PubMed ID: 20001457
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Renal denervation in comparison with intensified pharmacotherapy in true resistant hypertension: 2-year outcomes of randomized PRAGUE-15 study.
    Rosa J; Widimský P; Waldauf P; Zelinka T; Petrák O; Táborský M; Branny M; Toušek P; Čurila K; Lambert L; Bednář F; Holaj R; Štrauch B; Václavík J; Kociánová E; Nykl I; Jiravský O; Rappová G; Indra T; Krátká Z; Widimský J
    J Hypertens; 2017 May; 35(5):1093-1099. PubMed ID: 28118281
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluation and management of the patient with difficult-to-control or resistant hypertension.
    Viera AJ; Hinderliter AL
    Am Fam Physician; 2009 May; 79(10):863-9. PubMed ID: 19496385
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.